Jazz Pharmaceuticals appoints vice president of r&d
Jeffrey Tobias also takes chief medical officer role
Tobias has 20 years of experience in the biopharmaceutical industry across all phases of drug development, including regulatory filings in the US and Europe.
He has broad experience with a variety of therapeutic products spanning numerous clinical areas, including pain and neurological disorders.
Most recently, he was executive vice president of research and development at NeurogesX, where he has also been chief medical officer since 2005.
Prior to this Tobias was managing director of an independent biopharmaceutical consulting firm from 1996 to 2006, where he supported clients in all aspects of clinical development, technology assessment and strategic planning. He has also served in various roles in drug discovery and clinical development at ALZA, Chiron and XOMA.
Tobias also has 10 years of experience in clinical and academic medicine, focusing on internal and pulmonary and critical care medicine.
You may also like
Sustainability
Building strong foundations for a resilient and planet-friendly future
Having recently released its inaugural environmental, social and governance (ESG) report, Dr Kevin Robinson caught up with Gigi Bat-Erdene, Global ESG Program Manager at PCI Pharma Services, to find out how this leading CDMO is tackling climate science, workforce empowerment, responsible waste management and supply chain security
Regulatory
The key role of IVDs in healthcare: challenges to commercialisation and access
In simple terms, in vitro diagnostic (IVD) tests are done on samples such as blood or tissue that have been taken from the human body. IVDs can detect diseases, conditions and infections, provide patients with a better understanding of their ailment and how it might be managed and changed with treatment
